These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 7116298)

  • 1. The natural history of resectable metastatic melanoma (Stage IVA melanoma).
    Feun LG; Gutterman J; Burgess MA; Hersh EM; Mavligit G; McBride CM; Benjamin RS; Richman SP; Murphy WK; Bodey GP; Brown BW; Mountain CF; Leavens ME; Freireich EJ
    Cancer; 1982 Oct; 50(8):1656-63. PubMed ID: 7116298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): prognostic factors analysis and preliminary results of immunotherapy.
    Balch CM; Smalley RV; Bartolucci AA; Burns D; Presant CA; Durant JR
    Cancer; 1982 Mar; 49(6):1079-84. PubMed ID: 7037155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.
    Thatcher N; Mene A; Banerjee SS; Craig P; Gleave N; Orton C
    Br J Surg; 1986 Feb; 73(2):111-5. PubMed ID: 3512025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of adjuvant therapy in melanoma management.
    Barth A; Morton DL
    Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.
    Lipton A; Harvey HA; Balch CM; Antle CE; Heckard R; Bartolucci AA
    J Clin Oncol; 1991 Jul; 9(7):1151-6. PubMed ID: 2045856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma.
    Balch CM; Murray D; Presant C; Bartolucci AA
    Surgery; 1984 Apr; 95(4):454-9. PubMed ID: 6369594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant therapy of cutaneous malignant melanoma: a critical review.
    Koh HK; Sober AJ; Harmon DC; Lew RA; Carey RW
    Med Pediatr Oncol; 1985; 13(5):244-60. PubMed ID: 3897817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.
    Faries MB; Mozzillo N; Kashani-Sabet M; Thompson JF; Kelley MC; DeConti RC; Lee JE; Huth JF; Wagner J; Dalgleish A; Pertschuk D; Nardo C; Stern S; Elashoff R; Gammon G; Morton DL;
    Ann Surg Oncol; 2017 Dec; 24(13):3991-4000. PubMed ID: 29019177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.
    Can Med Assoc J; 1983 Apr; 128(8):929-33. PubMed ID: 6339024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical adjuvant therapy of malignant melanoma with corynebacterium parvum.
    Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Braun DW; Fortner JG; Oettgen HF
    Cancer; 1981 Jul; 48(2):245-51. PubMed ID: 7016302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma.
    Karakousis CP; Didolkar MS; Lopez R; Baffi R; Moore R; Holyoke ED
    Cancer Treat Rep; 1979; 63(11-12):1739-43. PubMed ID: 393377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCG immunotherapy in patients with malignant melanoma.
    Karakousis CP; Douglass HO; Yeracaris PM; Holyoke ED
    Arch Surg; 1976 Jun; 111(6):716-8. PubMed ID: 776125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant vemurafenib in resected, BRAF
    Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
    Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma.
    Thatcher N; Wagstaff J; Mene A; Smith D; Orton C; Craig P
    Eur J Cancer Clin Oncol; 1986 Aug; 22(8):1009-14. PubMed ID: 3770045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic parameters in recurrent malignant melanoma.
    Karakousis CP; Temple DF; Moore R; Ambrus JL
    Cancer; 1983 Aug; 52(3):575-9. PubMed ID: 6861095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.
    Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP
    N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-metastatic stage IV nasopharyngeal carcinoma patients: analysis of the pattern of relapse and survival.
    Ozyar E; Gurkaynak M; Yildiz F; Atahan IL
    Radiother Oncol; 2004 Jul; 72(1):71-7. PubMed ID: 15236877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
    Byrne MJ; Van Hazel G; Reynolds PM; Lemish WM; Holman CD
    J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.